Kerry Taylor

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2003 · 771 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +9

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2002 · 657 citations · Full text

Medicine, Hematology, Molecular Genetics +14

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study

Michael Hedenus, Magnus Adriansson, Jesús F. San Miguel et al. · British Journal of Haematology · 2003 · 326 citations · Full text

Medicine, Hematology, Pharmacology +10

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Jeffrey A. Jones, Tadeusz Robak, Jennifer R. Brown et al. · The Lancet Haematology · 2017 · 198 citations

Medicine, Oncology, Pharmacology +10